Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment
Obesity · 2023-05 · 31 (5) · 1270-1279
DOI: 10.1002/oby.23725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 23.02.2023. Verfasst von Jacob Levi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Medicine, Royal Free Hospital NHS Trust, London, UK. Hauptthemen laut MEDLINE: Liraglutide, Anti-Obesity Agents. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Objective
Novel antiobesity treatments are highly effective in recent clinical trials. Access to these medications is needed to supplement lifestyle and surgical interventions for millions living with obesity worldwide, but high prices are limiting. This study aimed to review current treatment costs and calculate potential estimated minimum prices (EMPs).
Methods
The authors searched national drug price databases across various countries for orlistat, naltrexone‐bupropion, topiramate‐phentermine, liraglutide, semaglutide, and tirzepatide. EMPs for antiobesity medications were calculated using established methodology, using active pharmaceutical ingredients (API) from the Panjiva database. EMPs were calculated per 30‐day course and include costs of active pharmaceutical ingredients, excipients, formulation, taxation, and 10% profit margin.
Results
National prices of antiobesity medications were significantly higher than calculated EMPs. Semaglutide 30‐day course prices ranged from $804 (United States) to $95 (Turkey) while the EMP was $40. Liraglutide prices ranged from $1418 (United States) to $252 (Norway) while the EMP was $50. Some oral treatments could be generically manufactured at very low costs per course ($7 for orlistat; $5 for phentermine/topiramate combination tablets), while naltrexone/bupropion was more expensive ($54).
Conclusions
This study shows that certain weight loss treatments can be manufactured and sold profitably at low costs, but prices currently range widely between countries, limiting access for those in need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Intensive Care Medicine, Royal Free Hospital NHS Trust, London, UK.
- Medical Sciences Office, Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.
- Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Department of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK.
ORCID-Profile: Jacob Levi, Junzheng Wang, Francois Venter, Andrew Hill
Förderung
- NHLBI NIH HHS
Zitieren
APA
Levi, J., Wang, J., Venter, F., & Hill, A. (2023). Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity, 31(5), 1270-1279. https://doi.org/10.1002/oby.23725
Vancouver
Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity. 2023;31(5):1270-1279. doi:10.1002/oby.23725
BibTeX
@article{Levi2023,
author = {Levi, Jacob and Wang, Junzheng and Venter, Francois and Hill, Andrew},
title = {Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment},
journal = {Obesity},
year = {2023},
volume = {31},
number = {5},
pages = {1270--1279},
doi = {10.1002/oby.23725}
}
EUVIMED